Characteristics | PGF* (n = 20) | GGF* (n = 40) | P value** |
---|---|---|---|
BM evaluated time (post-HSCT days) | 102 (53–152) | 92.5 (24–561) | 0.14 |
Blood cell count | |||
Median WBC (×109/L) (range) | 1.1 (0.3–2.7) | 5.01 (1.93–9.83) | <0.0001 |
Median ANC (×109/L) (range) | 0.7 (0.1–1.8) | 2.62 (0.84–7.1) | 0.0007 |
Median Hb (g/L) (range) | 83 (68–104) | 114.5 (85–165) | <0.0001 |
Median PLT (×109/L) (range) | 29 (4–53) | 149.5 (31–266) | <0.0001 |
Age at HSCT (years, median, range) | 33.5 (11–62) | 26 (7–51) | 0.10 |
Gender (male/female) | 15/5 | 24/16 | 0.39 |
Underlying disease | 0.78 | ||
AML | 6 | 14 | |
ALL | 9 | 16 | |
CML | 0 | 2 | |
MDS | 3 | 4 | |
sAA | 2 | 4 | |
Status at HSCT | 0.54 | ||
Standard-risk | 4 | 12 | |
High-risk | 16 | 24 | |
Source of stem cell | 0.99 | ||
BM and G-PB | 19 | 38 | |
G-PB | 1 | 2 | |
Transplanted total nucleated cell dose (×108/kg, median, range) | 8.08 (6.01–14.49) | 7.615 (5.22–13.81) | 0.68 |
Transplanted CD34+ cell dose (×108/kg, median, dose) | 2.29 (1.18–0.5.28) | 2.49 (0.85–6) | 0.09 |
Donor match | 0.34 | ||
HLA-identical unrelated donor | 1 | 2 | |
HLA-identical sibling donor | 3 | 12 | |
HLA-partially matched related | 16 | 26 | |
Sex mismatch | 0.99 | ||
Female to male | 5 | 9 | |
Female to female | 2 | 2 | |
Male to female | 4 | 13 | |
Male to male | 9 | 16 | |
ABO mismatch | 0.47 | ||
No | 12 | 26 | |
Minor | 3 | 6 | |
Major | 5 | 8 | |
Pre-HSCT cycles of chemotherapy | 4 (0–6) | 3.5 (0–11) | 0.86 |
Conditioning | 0.34 | ||
BU/CY | 3 | 12 | |
BU/CY + ATG | 17 | 28 | |
History of aGvHD | 13 | 21 | 0.77 |
History of CMV reactivation | 17 | 24 | 0.08 |